The pharma industry could add a whopping $564 billion per year to global sales if patients stuck to their drug regimens as prescribed, Capgemini consultants figure, based on estimates of $188 billion lost to poor adherence in the U.S. Report
The pharma industry could add a whopping $564 billion per year to global sales if patients stuck to their drug regimens as prescribed, Capgemini consultants figure, based on estimates of $188 billion lost to poor adherence in the U.S. Report